South Korea · Delayed Price · Currency is KRW NovMetaPharma Company Description
NovMetaPharma Co., Ltd. engages in the development and sale of drugs to treat metabolic diseases in South Korea.
The company is developing NovDB2, a type 2 diabetes medication; NovOB, an anti-obesity medication; NovRD, a chronic kidney disease medication; NovFS, a fibrosis medication; and NovRF, a retroperitoneal fibrosis medication.
It also develops drugs for inflammatory bowel; viral; vascular; bone loss; bone loss; cognitive impairment; Alzheimer’s; acute pancreatitis; degenerative brain; and liver cancer diseases, as well as cytokine inhibitor and exercise performance enhancement products.
The company was formerly known as PNC MetaPharm Co., Ltd. and changed its name to NovMetaPharma Co., Ltd. in May 2015.
NovMetaPharma Co., Ltd. was founded in 2010 and is headquartered in Seoul, South Korea.
| Country | South Korea |
| Founded | 2010 |
| Industry | Biological Products, Except Diagnostic Substances |
| CEO | Sun-Wook Hwang |
Contact Details
Address: Trees Building Seoul, 06050 South Korea | |
| Phone | 82 2 538 1893 |
| Website | novmeta.com |
Stock Details
| Ticker Symbol | 229500 |
| Exchange | Korea New Exchange |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Sun-Wook Hwang | Chief Executive Officer |